Teleflex Q2 revenue rises 29%, beats analyst estimates

Teleflex Incorporated

06/08/2026 11:46

Overview
U.S. medical technologies provider's Q2 revenue rose 29% yr/yr, beating analyst expectations
Adjusted EPS from continuing operations rose to $1.76 from $1.73 a year ago
Company completed OEM business sale, repaid debt, and repurchased $250 mln in stock

Outlook
Teleflex lowers 2026 GAAP revenue growth outlook to 13.4%-14.4%
Company cuts 2026 GAAP EPS guidance to $2.54-$2.84
Teleflex raises 2026 adjusted diluted EPS outlook to $6.90-$7.20

Result Drivers
VASCULAR AND SURGICAL GROWTH - Co said revenue growth was led by strong performance in its Vascular and Surgical businesses
INTEGRATION DELAYS - Co said integration of the acquired Biotronik Vascular Intervention business is taking longer than expected, affecting revenue outlook
INNOVATION PIPELINE - Co highlighted FDA approval for EZPLAZ and progress in the Freesolve clinical program as milestones in its innovation pipeline

Company press release: ID:nBw7znP7Xa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$570.30 mln
$559.60 mln (13 Analysts)
Q2 Adjusted EPS continuing operations
 
$1.76
 
Q2 EPS continuing operations
 
$0.96
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 10 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Teleflex Incorporated is $145.00, about 6% above its August 5 closing price of $136.78
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
Aug 4 - LeMaitre Vascular Q2 sales slightly miss estimates
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal
Aug 5 - Carlsmed Q2 revenue rises 57%, raises 2026 revenue forecast

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)